Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,076 matching trials from the live ClinicalTrials.gov search.
Conditions
COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
Interventions
BIO 300 Oral Suspension, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Houston, Texas
Conditions
Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Metabolic Disease
Interventions
Losartan, Zileuton, N-Acetylcysteine, Pravastatin, Erythromycin
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Results available

EASY: Extended Access to Sollpura Over Years

NCT02823964
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Jackson, Mississippi • Burlington, Vermont
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Completed No phase listed Observational Accepts healthy volunteers

Investigating Mucinase Activity in Airway Disease

NCT00596232
Conditions
Asthma, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
GB0139, Placebo
Drug
Lead sponsor
Galecto Biotech AB
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Palm Springs, California + 29 more
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
40 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
Cystic Fibrosis
Interventions
P-1037, Hypertonic Saline, Saline
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 30 more
Completed Not applicable Interventional Results available

Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT01118221
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
pulmonary rehabilitation
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Conditions
Vitamin D Deficiency, Cystic Fibrosis
Interventions
High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw
Dietary Supplement · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Completed No phase listed Observational

Cystic Fibrosis and Cognitive Function

NCT03820349
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Results available

Facilitating Communication Study

NCT03721952
Conditions
Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
Interventions
Facilitator-Based Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 2 Interventional Results available

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

NCT02730793
Conditions
Cystic Fibrosis
Interventions
Oral Aztreonam, Nasal Aztreonam, Nasal Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions
Values Inventory (VI)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Lung Transplant READY Pilot Study

NCT05135156
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention Control)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Miami, Florida • St. Petersburg, Florida
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo, Pirfenidone, Deupirfenidone
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 19 more
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia